About
Heat-Activated Liposomal Technology, Oncology
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Team (11)
Christine Pellizzari
Christine Pellizzari, JD
IMUNON
team_member
Donald Braun
Donald Braun, PhD
IMUNON
team_member
Douglas V
Douglas V. Faller, MD, PhD
IMUNON
team_member
Frederick J
Frederick J. Fritz
IMUNON
team_member
James E
James E. Dentzer
IMUNON
team_member
Khursheed Anwer
Khursheed Anwer, PhD, MBA
IMUNON
team_member
Clinical Trials (17)
View allTotal Trials
17
As Lead Sponsor
15
As Collaborator
2
Total Enrollment
2,036
By Phase
PHASE3: 3PHASE1/PHASE2: 4PHASE1: 5PHASE2: 5
By Status
COMPLETED: 8WITHDRAWN: 3RECRUITING: 2UNKNOWN: 2ACTIVE_NOT_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline17 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT06915025Lead Sponsor
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
PHASE3Recruiting
500 participants
Started: Jul 9, 2025 · Completed: Oct 31, 2032
NCT06283459Lead Sponsor
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
PHASE1/PHASE2Completed
24 participants
Started: Jun 4, 2024 · Completed: Mar 7, 2025
NCT05739981Lead Sponsor
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
PHASE1/PHASE2Recruiting
50 participants
Started: Feb 10, 2023 · Completed: Jan 30, 2028
NCT04852367Collaborator
PanDox: Targeted Doxorubicin in Pancreatic Tumours
PHASE1Withdrawn
Started: Jun 16, 2021 · Completed: Mar 30, 2023
NCT03393884Lead Sponsor
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
PHASE1/PHASE2Active, not recruiting
130 participants
Started: Sep 5, 2018 · Completed: Nov 30, 2025
Locations (1)
Headquarters
Lawrenceville, NJ, United States
Map
Loading map...